Free Trial

Erasca (ERAS) Stock Forecast & Price Target

Erasca logo
$1.48 -0.02 (-1.01%)
As of 10:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Erasca - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
5

Based on 5 Wall Street analysts who have issued ratings for Erasca in the last 12 months, the stock has a consensus rating of "Buy." Out of the 5 analysts, 5 have given a buy rating for ERAS.

Consensus Price Target

$4.80
225.42% Upside
According to the 5 analysts' twelve-month price targets for Erasca, the average price target is $4.80. The highest price target for ERAS is $6.00, while the lowest price target for ERAS is $3.00. The average price target represents a forecasted upside of 225.42% from the current price of $1.48.
Get the Latest News and Ratings for ERAS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Erasca and its competitors.

Sign Up

ERAS Analyst Ratings Over Time

TypeCurrent Forecast
3/25/24 to 3/25/25
1 Month Ago
2/24/24 to 2/23/25
3 Months Ago
12/26/23 to 12/25/24
1 Year Ago
3/26/23 to 3/25/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$4.80$5.70$5.90$8.00
Forecasted Upside225.42% Upside302.83% Upside129.57% Upside286.47% Upside
Consensus Rating
Buy
Buy
Moderate Buy
Moderate Buy
Remove Ads

ERAS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ERAS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Erasca Stock vs. The Competition

TypeErascaMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.82
2.54
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside222.15% Upside21,088.48% Upside16.92% Upside
News Sentiment Rating
Neutral News

See Recent ERAS News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/21/2025The Goldman Sachs Group
3 of 5 stars
Chris Shibutani
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$3.50 ➝ $3.00+92.93%
3/21/2025HC Wainwright
2 of 5 stars
Andres Maldonado
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00+305.40%
3/7/2025Morgan Stanley
3 of 5 stars
Jeffrey Hung
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$4.00 ➝ $4.00+167.56%
1/7/2025Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$5.00 ➝ $5.00+79.21%
11/18/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$6.00+124.72%
3/11/2024Capital One Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Quibria
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$8.00+250.88%
11/29/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$8.00 ➝ $7.00+270.37%
6/6/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$20.00 ➝ $11.00+233.33%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:53 AM ET.


ERAS Forecast - Frequently Asked Questions

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Erasca is $4.80, with a high forecast of $6.00 and a low forecast of $3.00.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Erasca in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ERAS shares.

According to analysts, Erasca's stock has a predicted upside of 225.42% based on their 12-month stock forecasts.

Over the previous 90 days, Erasca's stock had 1 upgrade by analysts.

Erasca has been rated by research analysts at Bank of America, HC Wainwright, Morgan Stanley, and The Goldman Sachs Group in the past 90 days.

Analysts like Erasca more than other "medical" companies. The consensus rating for Erasca is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ERAS compares to other companies.


This page (NASDAQ:ERAS) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners